Financial & competing interests disclosure
E Razvi works with companies in the miRNA and epigenetics fields, as well as producing market reports focusing on these areas. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
References
- Kan CW , HahnMA, GardGB et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer 12 , 627 (2012).
- Tijsen AJ , CreemersEE, MoerlandPD et al. Mir432–5p as a circulating biomarker for heart failure. Circ. Res. 106(6) , 1035–1039 (2010).
- Cortese R , KwanA, LalondeE et al. Epigenetic markers of prostate cancer in plasma circulating DNA. Hum. Mol. Genet. 21(16) , 3619–3631 (2012).
- Mo M -H, Chen L, Fu Y, Wang W, Fu SW. Cell-free circulating miRNA biomarkers in cancer. J. Cancer3 , 432–448 (2012).
- Duttagupta R , JiangR, GollubJ, GettsRC, JonesKW. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS ONE6(6) , e20769 (2011).
- Srivastava A , SuyS, CollinsSP, KumarD. Circulating microRNA as biomarkers: an update in prostate cancer. Mol. Cell. Pharmacol.3(3) , 115–124 (2011).
- Kosaka N , IguchiH, OhiyaT. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci.101(10) , 2087–2092 (2010).